-

$undefined

N/A

(N/A)

Eiger BioPharmaceuticals NASDAQ:EIGR Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis.

Location: 2155 Park Blvd, California, 94306-1543, US | Website: www.eigerbio.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.88M

Cash

44.43M

Avg Qtr Burn

-20.71M

Short % of Float

2.64%

Insider Ownership

11.80%

Institutional Own.

43.86%

Qtr Updated

09/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Zokinvy™ (lonafarnib) Details Progeroid laminopathies, Progeria, Hutchinson-Gilford progeria syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lonafarnib Details Liver disease, Infectious disease, Hepatitis D	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avexitide (GLP-1 Antagonist) Details Metabolic disorder, Congenital Hyperinsulinism	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avexitide (GLP-1 Antagonist) Details Post-Bariatric Hypoglycemia, Metabolic disorder, Rare diseases	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Peginterferon Lambda + Lonafarnib Details Infectious disease, Hepatitis D	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Peginterferon Lambda-1a (Lambda) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Peginterferon Lambda (Lambda) Details Infectious disease, Hepatitis D	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.